NCT04101331 · FLOW

Participant flow

Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides · Source last updated 2024-11-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

description
Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).
id
FG000
title
Cohort A

periods

drop Withdraws
reasons
group Id
FG000
num Subjects
9
type
Adverse Event
reasons
group Id
FG000
num Subjects
82
type
Disease progression
reasons
group Id
FG000
num Subjects
1
type
Withdrawal by Subject
reasons
group Id
FG000
num Subjects
6
type
Investigator decision
reasons
group Id
FG000
num Subjects
6
type
Death
reasons
group Id
FG000
num Subjects
1
type
Allogenic transplant
milestones
achievements
group Id
FG000
num Subjects
108
type
STARTED
achievements
group Id
FG000
num Subjects
3
type
COMPLETED
achievements
group Id
FG000
num Subjects
105
type
NOT COMPLETED
title
Overall Study

pre Assignment Details

All the subjects were screened for CD30 expression. Investigators assessed the subjects, and they were enrolled in the study if they met all inclusion criteria and none of the exclusion criteria.

recruitment Details

This study was a Phase II open-label multicenter study to assess the efficacy and safety of AFM13 in subjects with relapsed or refractory CD30-positive peripheral T-cell lymphoma.

Complete source fields